Systems and precision medicine approaches to diabetes heterogeneity: a Big Data perspective
Open accessAbstract
Big Data, and in particular Electronic Health Records, provide the medical community with a great opportunity to analyze multiple pathological conditions at an unprecedented depth for many complex diseases, including diabetes. How can we infer on diabetes from large heterogeneous datasets? A possible solution is provided by invoking next-generation computational methods and data analytics tools within systems medicine approaches. By deciphering the multi-faceted complexity of biological systems, the potential of emerging diagnostic tools and therapeutic functions can be ultimately revealed. In diabetes, a multidimensional approach to data analysis is needed to better understand the disease conditions, trajectories and the associated comorbidities. Elucidation of multidimensionality comes from the analysis of factors such as disease phenotypes, marker types, and biological motifs while seeking to make use of multiple levels of information including genetics, omics, clinical data, and environmental and lifestyle factors. Examining the synergy between multiple dimensions represents a challenge. In such regard, the role of Big Data fuels the rise of Precision Medicine by allowing an increasing number of descriptions to be captured from individuals. Thus, data curations and analyses should be designed to deliver highly accurate predicted risk profiles and treatment recommendations. It is important to establish linkages between systems and precision medicine in order to translate their principles into clinical practice. Equivalently, to realize their full potential, the involved multiple dimensions must be able to process information ensuring inter-exchange, reducing ambiguities and redundancies, and ultimately improving health care solutions by introducing clinical decision support systems focused on reclassified phenotypes (or digital biomarkers) and community-driven patient stratifications.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
High-throughput omics data has been central to developing precision medicine biomarkers for Alzheimer's, diabetes, cancer, hypertension, cardiovascular and chronic respiratory diseases.
“High-throughput generated omics data (Lightbody et al., 2019) has played a pivotal role in developing precision medicine biomarkers for diseases such as Alzheimer's (Hampel et al., 2017(Hampel et al., , 2016;;Kovacs, 2016), diabetes (Capobianco, 2017;McCarthy, 2017;Mutie et al., 2017), cancer (Borad and LoRusso, 2017;Senft et al., 2017), hypertension (Barnes et al., 2016;Dominiczak et al., 2017),”
From Using machine learning approaches for multi-omics data analysis: A review (2021) · cites this paper as Capobianco, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 43 · Cited by 39
- Authors
- Capobianco, E.
- Affiliations
- University of Miami (US)
- Corresponding author
- Capobianco, Enrico
- ORCID
- Capobianco, Enrico
- Venue
- Clinical and Translational Medicine
- Publisher
- Wiley
- Published
- 2017-07-25
- Volume
- 6
- Issue
- 1
- Pages
- 23-23
- ISSN
- 2001-1326 (ISSN-L)
- PMC
- PMC5526830
- OpenAlex
- W2738759181
- Cited by
- 39
- References
- 43
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 3 · 2019: 9 · 2018: 6
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical and Translational Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Computer Science › Artificial Intelligence › Machine Learning in Healthcare
- Health Sciences › Health Professions › Health Information Management › Artificial Intelligence in Healthcare
- Health Sciences › Health Professions › Health Information Management › Electronic Health Records Systems
- Keywords
- diabetes heterogeneity, systems medicine, precision medicine, electronic health records, big data, diabetes phenotypes, digital biomarkers, clinical decision support, patient stratification, comorbidities, multi-omics integration, risk prediction, treatment guidelines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review